We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Read MoreHide Full Article
Shares of Moderna (MRNA - Free Report) declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID. Per the company, the decision was taken in consultation with the agency.
This announcement did not come as a surprise since MRNA had already announced earlier this month, alongside its Q1 results, that the FDA had requested ‘Phase 3 flu efficacy data.’ This setback derailed the company’s initial plans to secure a potential FDA approval for the vaccine before this year’s end.
Moderna plans to resubmit this filing later this year after vaccine efficacy data from the ongoing phase III study on its investigational seasonal influenza vaccine, mRNA-1010, is available. Interim data from this study is expected this summer.
The initial FDA filing, which sought approval for use in older adults aged 50 years and above, was supported by data from a phase III study announced last year. Data from this study showed that mRNA-1083 elicited higher immune responses against influenza and COVID compared with licensed standalone influenza and COVID vaccines.
MRNA Stock Price Performance
Year to date, Moderna’s shares have plummeted 38% compared to the industry’s 4% fall.
Image Source: Zacks Investment Research
Other Players Developing COVID-Flu Combination Shots
Apart from Moderna, Novavax (NVAX - Free Report) , Pfizer (PFE - Free Report) and Sanofi (SNY - Free Report) are also developing their respective COVID/flu combination vaccines.
NVAX started a late-stage study last year evaluating its experimental COVID-influenza combination (CIC) vaccine candidate. This study is comparing the immunogenicity and safety of the CIC vaccine against separate administrations of Novavax’s currently authorized COVID vaccine and a licensed seasonal influenza vaccine. Initial data from this study is expected later this year.
Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. PFE is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech.
A recent entrant into this space is Sanofi, which is also developing its own COVID/flu combination vaccines. Last year, SNY announced that the FDA granted fast-track designation to two of its experimental combination vaccines for COVID and influenza, each being evaluated in separate phase I/II studies. While the first combination pairs the Fluzone HD vaccine with Novavax’s COVID vaccine, the second combines Sanofi’s Flubok influenza vaccine with the NVAX COVID vaccine.
Image: Bigstock
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Shares of Moderna (MRNA - Free Report) declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID. Per the company, the decision was taken in consultation with the agency.
This announcement did not come as a surprise since MRNA had already announced earlier this month, alongside its Q1 results, that the FDA had requested ‘Phase 3 flu efficacy data.’ This setback derailed the company’s initial plans to secure a potential FDA approval for the vaccine before this year’s end.
Moderna plans to resubmit this filing later this year after vaccine efficacy data from the ongoing phase III study on its investigational seasonal influenza vaccine, mRNA-1010, is available. Interim data from this study is expected this summer.
This decision also comes a day after the FDA issued new guidance for COVID vaccine boosters. As part of this guidance, COVID vaccine makers will be required to conduct randomized, placebo-controlled clinical studies demonstrating the real-world benefit of yearly COVID vaccine boosters in individuals aged under 65 years.
The initial FDA filing, which sought approval for use in older adults aged 50 years and above, was supported by data from a phase III study announced last year. Data from this study showed that mRNA-1083 elicited higher immune responses against influenza and COVID compared with licensed standalone influenza and COVID vaccines.
MRNA Stock Price Performance
Year to date, Moderna’s shares have plummeted 38% compared to the industry’s 4% fall.
Image Source: Zacks Investment Research
Other Players Developing COVID-Flu Combination Shots
Apart from Moderna, Novavax (NVAX - Free Report) , Pfizer (PFE - Free Report) and Sanofi (SNY - Free Report) are also developing their respective COVID/flu combination vaccines.
NVAX started a late-stage study last year evaluating its experimental COVID-influenza combination (CIC) vaccine candidate. This study is comparing the immunogenicity and safety of the CIC vaccine against separate administrations of Novavax’s currently authorized COVID vaccine and a licensed seasonal influenza vaccine. Initial data from this study is expected later this year.
Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. PFE is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech.
A recent entrant into this space is Sanofi, which is also developing its own COVID/flu combination vaccines. Last year, SNY announced that the FDA granted fast-track designation to two of its experimental combination vaccines for COVID and influenza, each being evaluated in separate phase I/II studies. While the first combination pairs the Fluzone HD vaccine with Novavax’s COVID vaccine, the second combines Sanofi’s Flubok influenza vaccine with the NVAX COVID vaccine.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
MRNA’s Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.